MedTrace Logo

Extended Follow-up of Women Who Received One, Two, and Three Doses of the HPV Vaccine in the Costa Rica Vaccine Trial (CVT), ESCUDDO-CVT Study

NCT03309033 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 946

Last updated 2026-05-13

No results posted yet for this study

Summary

This study is extending follow up of women who participated in the Costa Rica Vaccine Trial (CVT) and received one dose or two doses of the human papillomavirus (HPV) vaccine, along with a group of women who received three doses. It also studies the stability of HPV defenses in these groups of women for up to 20 years after initial vaccination. Studying samples of blood in the laboratory may provide information on how long one, two, and three doses of the vaccine provide protection against HPV. The results of this study may also help researchers learn whether one dose of HPV vaccine is enough to protect against HPV.

Conditions

  • Human Papillomavirus Infection
  • Human Papillomavirus-Related Malignant Neoplasm

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Questionnaire Administration

Complete questionnaire

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Aimee R Kreimer · National Cancer Institute (NCI)

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-02
Primary Completion
2026-03-05
Completion
2028-12-31

Countries

  • Costa Rica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309033 on ClinicalTrials.gov